In vivo structural activity and optimization studies of folate-tubulysin conjugates

Molecular Pharmaceutics

Volumn 6, Issue 5, 2009, Pages 1518-1525

  Reddy, Joseph A ^a   Dorton, Ryan ^a   Dawson, Alicia ^a   Vetzel, Marilynn ^a   Parker, Nikki ^a   Nicoson, Jeffrey S ^a   Westrick, Elaine ^a   Klein, Patrick J ^a   Wang, Yu ^a   Vlahov, Iontcho R ^a   Leamon, Christopher P ^a,b  

^a Endocyte Inc   (United States)

^b NONE   (United States)

Author keywords

Cancer; Folate receptor; Targeted chemotherapy; Tubulysin; Tumor

Indexed keywords

EC 0302; EC 0305; EC 0317; EC 0510; EC 145; FOLATE BINDING PROTEIN; FOLATE PLUS DESACETYLVINBLASTINE MONOHYDRAZIDE; FOLATE PLUS TUBULYSIN A HYDRAZIDE; FOLATE PLUS TUBULYSIN B ESTER; FOLATE PLUS TUBULYSIN B HYDRAZIDE; FOLATE PLUS TUBULYSIN E HYDRAZIDE; FOLATE RECEPTOR; FOLIC ACID; TUBULYSIN A; TUBULYSIN B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DOSE INCREASE; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; HUMAN; NASOPHARYNX CANCER; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CARRIER PROTEINS; CATTLE; CELL LINE, TUMOR; DOGS; FEMALE; FOLIC ACID; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; PROTEIN BINDING; RABBITS; RATS; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350070854     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900086w     Document Type: Conference Paper

References (37)

1. Low, P. S.; Antony, A. C. e. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug Delivery Rev. 2004, 56 (8), 1055-1231. (Pubitemid 38496506)
2. Leamon, C. P.; Low, P. S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discovery Today 2001, 6 (1), 44-51. (Pubitemid 32156966)
3. Reddy, J. A.; Low, P. S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. 1998, 15 (6), 587-627.
4. Reddy, J. A.; Allagadda, V. M.; Leamon, C. P. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr. Pharm. Biotechnol. 2005, 6 (2), 131-150.
5. Reddy, J. A.; Leamon, C. P.; Low, P. S. Folate-Mediated Delivery of Protein and Peptide Drugs into Tumors. In Delivery of Protein and Peptide drugs in Cancer; Torchilin, V., Ed.; World Scientific/Imperial College Press: London, 2006; pp 183-204.
6. Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 1997, 74 (2), 193-198. (Pubitemid 27234510)
7. Ross, J. F.; Chaudhuri, P. K.; Ratnam, M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994, 73 (9), 2432-2443. (Pubitemid 24129130)
8. Weitman, S. D.; Weinberg, A. G.; Coney, L. R.; Zurawski, V. R.; Jennings, D. S.; Kamen, B. A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 1992, 52 (23), 6708-6711.
9. Leamon, C. P.; Low, P. S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U.S.A. 1991, 88 (13), 5572-5576.
10. Leamon, C. P.; Low, P. S. Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem. J. 1993, 291 (Part 3), 855-860.
11. Leamon, C. P.; Reddy, J. A.; Vlahov, I. R.; Westrick, E.; Parker, N.; Nicoson, J. S.; Vetzel, M. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int. J. Cancer 2007, 121 (7), 1585-1592. (Pubitemid 47328719)
12. Reddy, J. A.; Westrick, E.; Vlahov, I.; Howard, S. J.; Santhapuram, H. K.; Leamon, C. P. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother. Pharmacol. 2006, 58 (2), 229-236.
13. Ladino, C. A.; Chari, R. V.; Bourret, L. A.; Kedersha, N. L.; Goldmacher, V. S. Folate-maytansinoids: target-selective drugs of low molecular weight. Int. J. Cancer 1997, 73 (6), 859-864.
14. Reddy, J. A.; Dorton, R.; Westrick, E.; Dawson, A.; Smith, T.; Xu, L. C.; Vetzel, M.; Kleindl, P.; Vlahov, I. R.; Leamon, C. P. Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate. Cancer Res. 2007, 67 (9), 4434-4442.
15. Reddy, J. A.; Abburi, C.; Hofland, H.; Howard, S. J.; Vlahov, I.; Wils, P.; Leamon, C. P. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 2002, 9 (22), 1542-1550.
16. Lee, R. J.; Low, P. S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 1994, 269 (5), 3198-3204. (Pubitemid 24237629)
17. Lu, Y.; Low, P. S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 2002, 51 (3), 153-162.
18. Rund, L. A.; Cho, B. K.; Manning, T. C.; Holler, P. D.; Roy, E. J.; Kranz, D. M. Bispecific agents target endogenous murine T cells against human tumor xenografts. Int. J. Cancer 1999, 83 (1), 141-149.
19. Leamon, C. P.; Reddy, J. A.; Vlahov, I. R.; Westrick, E.; Dawson, A.; Dorton, R.; Vetzel, M.; Santhapuram, H. K.; Wang, Y. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol. Pharmaceutics 2007, 4 (5), 659-667. (Pubitemid 350004265)
20. Leamon, C. P.; Reddy, J. A.; Vetzel, M.; Dorton, R.; Westrick, E.; Parker, N.; Wang, Y.; Vlahov, I. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res. 2008, 68 (23), 9839-9844.
21. Neri, D.; Fossati, G.; Zanda, M. Efforts toward the total synthesis of tubulysins: new hopes for a more effective targeted drug delivery to tumors. ChemMedChem 2006, 1 (2), 175-180.
22. Peltier, H. M.; McMahon, J. P.; Patterson, A. W.; Ellman, J. A. The Total Synthesis of Tubulysin D. J. Am. Chem. Soc. 2006, 128 (50), 16018-16019.
23. Balasubramanian, R.; Raghavan, B.; Begaye, A.; Sackett, D. L.; Fecik, R. A. Total synthesis and biological evaluation of tubulysin U, tubulysin V, and their analogues. J. Med. Chem. 2009, 52 (2), 238-240.
24. Wang, Z.; McPherson, P. A.; Raccor, B. S.; Balachandran, R.; Zhu, G.; Day, B. W.; Vogt, A.; Wipf, P. Structure-activity and high-content imaging analyses of novel tubulysins. Chem. Biol. Drug Des. 2007, 70 (2), 75-86.
25. Schluep, T.; Gunawan, P.; Ma, L.; Jensen, G. S.; Duringer, J.; Hinton, S.; Richter, W.; Hwang, J. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin. Cancer Res. 2009, 15 (1), 181-189.
26. Patterson, A. W.; Peltier, H. M.; Sasse, F.; Ellman, J. A. Design, synthesis, and biological properties of highly potent tubulysin D analogues. Chemistry 2007, 13 (34), 9534-9541.
27. Sasse, F.; Steinmetz, H.; Heil, J.; Hofle, G.; Reichenbach, H. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. J. Antibiot. (Tokyo) 2000, 53 (9), 879-885.
28. Steinmetz, H.; Glaser, N.; Herdtweck, E.; Sasse, F.; Reichenbach, H.; Hofle, G. Isolation, crystal and solution structure determination, and biosynthesis of tubulysins - powerful inhibitors of tubulin polymerization from myxobacteria. Angew. Chem., Int. Ed. Engl. 2004, 43 (37), 4888-4892.
29. Kaur, G.; Hollingshead, M.; Holbeck, S.; Schauer-Vukasinovic, V.; Camalier, R. F.; Domling, A.; Agarwal, S. Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem. J. 2006, 396 (2), 235-242. (Pubitemid 43837239)
30. Xu, L.; Vlahov, I. R.; Leamon, C. P.; Santhapuram, H. K. R.; Li, C. H. Synthesis and purification of pteroic acid and conjugates thereof. 06009153/US2006.
31. Vlahov, I. R.; Wang, Y.; Kleindl, P. J.; Leamon, C. P. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides. Bioorg. Med. Chem. Lett. 2008, 18 (16), 4558-4561.
32. Vlahov, I.; Wang, Y.; Leamon, C. P. Tubulysins and processes for preparing. PCT/US2008/080948, 2008.
33. Spinella, M. J.; Brigle, K. E.; Sierra, E. E.; Goldman, I. D. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J. Biol. Chem. 1995, 270 (14), 7842-7849.
34. Mathias, C. J.; Wang, S.; Lee, R. J.; Waters, D. J.; Low, P. S.; Green, M. A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 1996, 37 (6), 1003-1008.
35. Zhou, X. J.; Rahmani, R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992, 44 (Suppl. 4), 1-16; discussion, pp 66-69.
36. Leamon, C. P.; Parker, M. A.; Vlahov, I. R.; Xu, L. C.; Reddy, J. A.; Vetzel, M.; Douglas, N. Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjugate Chem. 2002, 13 (6), 1200-1210.
37. Leamon, C. P.; Reddy, J. A.; Vlahov, I. R.; Vetzel, M.; Parker, N.; Nicoson, J. S.; Xu, L. C.; Westrick, E. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjugate Chem. 2005, 16 (4), 803-811. (Pubitemid 41026166)